Michele Farmer, Chief Accounting Officer at Pacific Biosciences of California, Inc. (NASDAQ: PACB), executed a sale of 2,979 shares of the company's common stock on March 3, 2026. The transaction carried a weighted average sale price of $1.514 per share for an aggregate value of $4,510. Reported trade prices ranged between $1.49 and $1.56.
Following the disposition, Farmer retains direct ownership of 305,948 Pacific Biosciences shares. The company reported that the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units.
Quarterly results highlighted alongside the insider sale
In an earnings update for the fourth quarter of 2025, Pacific Biosciences posted results that exceeded market expectations. The company reported an earnings per share (EPS) loss of -$0.12, compared with the -$0.15 per share analysts had expected. That EPS print represents a 20% positive surprise relative to consensus.
Revenue for the quarter was $44.6 million, above the forecasted $42.27 million and constituting a 5.51% upside versus estimates. The company characterized the announcement as a notable development for investors.
Context and clarity
The share sale by Farmer was disclosed as a tax-withholding action related to restricted stock unit vesting. The transaction details - number of shares sold, price range, weighted average price, and remaining direct ownership - are presented in the company filing. Separately disclosed financial results for Q4 2025 indicate the company recorded a smaller-than-expected loss per share and revenue above consensus.
No additional motivations or forward-looking statements tied to the insider sale were provided beyond the stated tax withholding purpose. Likewise, the financial release contained the EPS and revenue figures noted above but did not include other performance metrics or guidance in the information furnished here.